Lowering Drug Prices by Putting America First

What it means

Aims to lower prescription drug prices in Medicare Part B by ensuring the US pays no more than the lowest price offered to other developed nations. This establishes a "most-favored-nation price" model to address the issue of Americans paying the highest drug prices globally.

Expected impact

• Potential reduction in Medicare Part B drug prices, particularly benefiting seniors and fixed-income Americans
• Savings for both Medicare beneficiaries and taxpayers through lower prescription costs
• Possible resistance from pharmaceutical companies who may see reduced profits
• Improved medication adherence as patients become more able to afford their prescribed treatments
• May shift some drug development costs currently borne primarily by American consumers to be more evenly distributed globally